Share on LinkedInShare on LinkedIn

ARTICLE · 09 MARCH 2022

Spotlight On Upcoming Oral Arguments - March 2022

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The following telephone arguments will be available to the public live. Access information will be available by 9 AM ET each day of argument at: http://www.cafc.uscourts.gov/public-access-arguments.

United StatesIntellectual Property

The following telephone arguments will be available to the public live.  Access information will be available by 9 AM ET each day of argument at: http://www.cafc.uscourts.gov/public-access-arguments.

Wednesday, March 9, 2022

Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc., No. 21-1981

Mylan petitioned for inter partes review (“IPR”) of Sanofi's U.S. Patent No. RE47,614, challenging the claims as obvious over, among others, a secondary prior art reference de Gennes. In concluding the challenged claims were obvious, the Board determined de Gennes is analogous art in this particular case to the '614 patent under the reasonable pertinence prong of the test for analogous art in this case.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from